ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "IL-1"

  • Abstract Number: 028 • 2020 Pediatric Rheumatology Symposium

    A Randomized, Double-blind, Placebo-controlled Study of Anakinra in Pediatric and Adult Patients with Still’s Disease

    Laura Schanberg1, Peter Nigrovic 2, Ashley Cooper 3, Winn Chatham 4, Shoghik Akoghlanian 5, Namrata Singh 6, C. Egla Rabinovich 7, Akaluck Thatayatikom 8, Alysha Taxter 9, Jonathan Hausmann 10, Milan Zdravkovic 11, Sven Ohlman 11, Henrik Andersson 11, Susanna Cederholm 12, Gunilla Huledal 11, Rayfel Schneider 13 and Fabrizio De Benedetti 14, 1Duke Children's Hospital & Health Center, Durham, North Carolina, 2Boston Children's Hospital, Boston, Massachusetts, 3Children's Mercy Kansas City, Kansas City, 4University of Alabama at Birmingham, Birmingham, 5Nationwide Children's Hospital, Columbus, 6University of Iowa Hospitals and Clinics, Iowa, Iowa, 7Duke University Hospital, Durham, 8University of Florida, Gainesville, 9Wake Forest Baptist Medical Center, Winston-Salem, 10Division of Immunology, Boston Children's Hospital; Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, 11Sobi, Stockholm, Sweden, 12Stockholm, Sweden, 13The Hospital for Sick Children, Toronto, Canada, 14Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy

    Background/Purpose: Adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) are rare systemic disorders of auto-inflammatory nature. There is a growing understanding that SJIA…
  • Abstract Number: 1238 • 2019 ACR/ARP Annual Meeting

    Monosodium Urate and Calcium Pyrophosphatecrystal-induced Interleukin 1 Production Depends on Glucose Uptake Through Glut1 Transporter

    Félix Renaudin 1, Laure Campillo-Gimenez 2, Florence Castelli 3, François Fenaille 3, Aurélie Prignon 4, Christele Combes 5, Martine Cohen-Solal 1, Frédéric Lioté 6 and Hang Korng Ea1, 1Université Paris, INSERM UMR1132 BIOSCAR, Paris, France, 2Université Paris, INSERM UMR1132 BIOSCAR, San Diego, 3CEA Paris-Saclay, Laboratoire d’Etudes du Métabolisme des Médicaments, Saclay, France, 4UMS28 Phénotypage du petit animal, Laboratoire d'Imagerie Moléculaire Positonique (LIMP), Sorbonne Univerity, Paris, France, 5CIRIMAT, Université de Toulouse, INPT,UPS,CNRS,ENSIACET, Toulouse, France, 6Rheumatology Department, Lariboisiere Hospital, AP-HP, Paris, France, Paris, France

    Background/Purpose: Monosodium urate (MSU) andmonoclinic calcium pyrophosphate dihydrated(mCPPD)crystals are responsible for relapsing acute arthritis which is driven by interleukin 1β (IL-1β).IL-1βproductionrelies onNLRP3 inflammasome activationleading to…
  • Abstract Number: 2905 • 2019 ACR/ARP Annual Meeting

    Rilonacept in Recurrent Pericarditis: Efficacy and Safety Data from an Ongoing Phase 2 Pilot Clinical Trial

    Allan Klein 1, David Lin 2, Paul Cremer 1, Saifullah Nasir 3, Sharon Crugnale 4, Larisa Collins 4, Fang Fang 4, Anna Beutler 4 and John F Paolini4, 1Cleveland Clinic, Cleveland, OH, 2Minneapolis Heart Institute - Minneapolis, Minneapolis, MN, 3Stat! Cardiologist, Chicago, IL, 4Kiniksa Pharmaceuticals Corp, lexington, MA

    Background/Purpose: Recurrent pericarditis (RP) is characterized by the recurrence of pericarditis signs and symptoms after a symptom-free period of ≥4 to 6 weeks and affects…
  • Abstract Number: 2855 • 2018 ACR/ARHP Annual Meeting

    Expanding the Phenotype: New Variant in the IL1RN-Gene Associated with Late Onset and Atypical Presentation of Dira

    Jasmin B. Kuemmerle-Deschner1, Konstanze Hoertnagel2, Susanne Schlipf3, Sandra Hansmann4, Toni Hospach5, Ilias Tsiflikas6, Xiao Liu7, Susanne Benseler8 and Alexander Weber7, 1Department of Pediatrics, Division of Rheumatology, University Hospital Tuebingen, Germany, Tuebingen, Germany, 2Praxis für Humangenetik Tübingen,Tuebingen, Germany, Tuebingen, Germany, 3Kinderarztpraxis Dr. Lakner, Schwäbisch Gmünd, Germany, Schwäbisch Gmünd, Germany, 4Department of Pediatrics, Division of Pediatric Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, Tuebingen, Germany, 5Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgart, Germany, 6Division of Pediatric Radiology, Department of Radiology, University Hospital Tuebingen, Germany, Tuebingen, Germany, 7Department of Immunology, University of Tübingen, Tübingen, Germany, Tuebingen, Germany, 8Rheumatology, Department of Paediatrics, Alberta Children's Hospital, University of Calgary, Alberta, Canada, Calgary, AB, Canada

    Background/Purpose: Deficiency of the Interleukin-1 receptor antagonist (DIRA) is an autoinflammatory disease of infancy characterized by severe systemic inflammation with bone and skin involvement. This…
  • Abstract Number: 2965 • 2018 ACR/ARHP Annual Meeting

    Targeting Glucose Metabolism in the Murine Air Pouch Model of Acute Gouty Inflammation

    Anyan Cheng1, Roxana Coras1,2, Robert Terkeltaub3,4, Ru Liu-Bryan1,3 and Monica Guma1,2, 1Medicine, University of California San Diego, La Jolla, CA, 2Medicine, Autonomous University of Barcelona, Bellatera, Spain, 3VA San Diego Healthcare System, San Diego, CA, 4Medicine, Division of Rheumatology, Allergy and Immunology. UCSD., La Jolla, CA

    Background/Purpose: Emerging evidence indicates that macrophage activation is critically supported by glucose metabolic shifts. Although macrophages are key contributors to inflammation, little is known about…
  • Abstract Number: 2968 • 2018 ACR/ARHP Annual Meeting

    Role of Choline in Gouty Inflammation

    Elsa Sanchez-Lopez1, Zhenyu Zhong1, Alex Stubelius2, Shannon R Sweeney3, Ru Liu-Bryan4,5, Juan Carlos Lacal6, Stefano Tiziani3,7,8, Robert Terkeltaub4,9, Monica Guma9 and Michael Karin1, 1Department of Pharmacology, School of Medicine. UCSD., La Jolla, CA, 2Division of Rheumatology, Allergy and Immunology. UCSD., La Jolla, CA, 3Department of Nutritional Sciences. The University of Texas at Austin., Austin, TX, 4VA San Diego Healthcare System, San Diego, CA, 5Medicine-Rheumatology, Division of Rheumatology, Allergy and Immunology. UCSD., La Jolla, CA, 6Translational Oncology. Department of Oncology, Hospital Universitario Fuenlabrada, Madrid, Spain, 7Department of Molecular Biosciences, College of Natural Sciences. The University of Texas at Austin., Austin, TX, 8Department of Pediatrics, Dell Medical School. The University of Texas at Austin., Austin, TX, 9Medicine, Division of Rheumatology, Allergy and Immunology. UCSD., La Jolla, CA

    Background/Purpose: Gout is characterized by deposition of monosodium urate (MSU) crystals in articular joints, where they activate macrophages inducing NLRP3 inflammasome activation and bioactive IL-1β…
  • Abstract Number: 1985 • 2018 ACR/ARHP Annual Meeting

    IL-1β Inhibits the Expression of Dickkopf-1, an Antagonist of the Wnt-β-Catenin Signaling Pathway: A Possible Role of Inflammasome in Dysregulation of Endochondral Ossification

    Satoshi Yamasaki1, Yusuke Yoshida2, Katsuhiro Oi2, Tatsuomi Kuranobu2, Takaki Nojima2, Hiroaki Ida3 and Eiji Sugiyama4, 1Division of Rheumatology, Kurume University Medical Center, Fukuoka, Japan, 2Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, 3Respiorogy, Neurology and Rheumatology, Kurume University School of Medicine, Kurume, Japan, 4Department of Clinical Immunology and Rheumatology, Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan

    Background/Purpose: Aberrant endochondral bone formation in the physis is a unique bone lesion in neonatal-onset multisystem inflammatory disease (NOMID), also called chronic infantile neurologic cutaneous…
  • Abstract Number: 76 • 2017 ACR/ARHP Annual Meeting

    TNF-α Potentiates Uric Acid-Induced Interleukin-1β Secretion in Human Neutrophils

    Shuzo Sato1, Makiko Yashiro1, Tomoyuki Asano1, Tomohiro Koga2, Eiji Suzuki1, Hiroko Kobayashi1, Hiroshi Watanabe1 and Kiyoshi Migita3, 1Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan, 2Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 3Fukushima Medical University School of Medicine, Fukushima, Japan

    Background/Purpose: Gout is an inflammatory arthropathy due to the deposition of uric acid (monosodium urate: MSU) crystals in synovial tissue. MSU leads to activate nucleotide-binding…
  • Abstract Number: 77 • 2017 ACR/ARHP Annual Meeting

    Platelets Induce IL-1b Production in Human Monocytes through NLRP3 Inflammasome Activation

    Shota Nakano1, Hiroki Mitoma1, Shotaro Kawano1, Shoichiro Inokuchi2, Masahiro Ayano1, Yasutaka Kimoto3, Mitsuteru Akahoshi1, Yojiro Arinobu1, Koichi Akashi1, Takahiko Horiuchi4 and Hiroaki Niro5, 1Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, 2Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan, 3Department of Internal Medicine, Kyushu University Beppu Hospital, Oita, Japan, 4Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, 5Department of Medical Education, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan

    Background/Purpose: Recent studies have revealed that platelets play pivotal roles in inflammation in addition to hemostasis. The thrombus induces subsequent local inflammation and reversely the…
  • Abstract Number: 1163 • 2017 ACR/ARHP Annual Meeting

    A First-in-Human Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Novel Anti-Interleukin 1 Biologic Agent, Rph-104, in Healthy Subjects

    Ahmet Gul1, Sibel Ulker2, Recep Selim Senturk2, Ugur Onsel Turk2, Cemil Gurgun2, Yan Lavrovsky3, Mikhail Samsonov4, Sebnem Ozen5 and Serdar Altinel6, 1Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 2Ege University Drug Development and Pharmacokinetics Research and Application Centre (ARGEFAR), Izmir, Turkey, 3R-Pharm Overseas, Inc.,, San Diego, CA, 4Medical Department, R-Pharm JSC, Moscow, Russian Federation, 5Clinical Trial Department, TRPHARM İlac A.S., Istanbul, Turkey, 6linical Trial Department, TRPHARM İlac A.S., Istanbul, Turkey

    Background/Purpose: Interleukin-1 (IL-1) is highly active pro-inflammatory cytokine, which is responsible for clinical and laboratory findings in hereditary and acquired auto-inflammatory disorders. Blocking IL-1 activity…
  • Abstract Number: 1196 • 2017 ACR/ARHP Annual Meeting

    Safety and Efficacy of ABT-981, an Anti–Interleukin-1α/β Dual Variable Domain (DVD) Immunoglobulin, in Subjects with Knee Osteoarthritis: Results from the Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2 Trial

    Roy Fleischmann1, Henning Bliddal2, Francisco J Blanco3, Thomas J. Schnitzer4, Charles Peterfy5, Su Chen6, Li Wang6, Philip G. Conaghan7, Francis Berenbaum8, Jean-Pierre Pelletier9, Johanne Martel-Pelletier9, Ole Vaeterlein10, Wei Liu6, Gwen Levy6, Lanju Zhang6, Jeroen K. Medema6 and Marc C. Levesque6, 1University of Texas Southwestern Medical Center at Dallas, Metroplex Clinical Research Center, Dallas, TX, 2Parker Institute, Bispebjerg-Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark, 3INIBIC-Instituto de Investigaciones Biomédicas de A Coruña-Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain, 4Northwestern Medicine, Feinberg School of Medicine, Chicago, IL, 5Spire Sciences, Inc., Boca Raton, FL, 6AbbVie Inc., North Chicago, IL, 7Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 8University Pierre & Marie Curie and Inserm, DHU i2B, APHP, Hospital Saint-Antoine, Paris, France, 9Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, 10Bioclinica, Hamburg, Germany

    Background/Purpose: Animal studies suggested that inhibiting IL-1α/β with ABT-981 may reduce pain and slow structural progression in OA. This study (NCT02087904; ILLUSTRATE-K) assessed the safety…
  • Abstract Number: 1211 • 2017 ACR/ARHP Annual Meeting

    Biomarkers Predictive of Pain Improvement in Knee Osteoarthritis Subjects Treated with the Anti-IL-1α/β Dual Variable Domain Immunoglobulin ABT-981

    Sheng Feng1, Su Chen1, Li Wang1, Charles Peterfy2, Virginia B. Kraus3, Rajesh Kamath1, Lanju Zhang1, Yanping Luo1, Lu Cui1, Jeroen K. Medema1 and Marc C. Levesque1, 1AbbVie Inc., North Chicago, IL, 2Spire Sciences, Inc., Boca Raton, FL, 3Duke University School of Medicine, Durham, NC

    Background/Purpose: Development of disease-modifying drugs for OA has been challenging, partly due to lack of predictive biomarkers. Our primary objective was to identify baseline (BL)…
  • Abstract Number: 2083 • 2017 ACR/ARHP Annual Meeting

    The Inflammation Induced By Four Types of Calcium Pyrophosphate Crystals Depends on Their Capacity to Stimulate NF-κb and MAPK Pathways

    Félix Renaudin1, Laure Campillo-Gimenez2, Pierre Gras3, Christèle Combes4, Martine Cohen-Solal1, Frederic Liote5 and Hang-Korng Ea1, 1INSERM UMR1132, Paris Diderot University, Paris, France, 2Inserm UMR1132 Bioscar, Paris, France, 3CIRIMAT, INPT-UPS-CNRS, Toulouse, France, 4ENSIACET, CIRIMAT, INPT-UPS-CNRS, Toulouse, France, 5University Paris Diderot, Paris, France

    Background/Purpose: Calcium pyrophosphate (CPP) crystal-induced inflammation is mainly driven by interleukin (IL)-1β. IL-1β production involves a two-step process including the formation of pro-IL-1β through NF-κB…
  • Abstract Number: 74 • 2017 Pediatric Rheumatology Symposium

    Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis

    Esraa M. A. Eloseily1,2, Peter Weiser1, Hilary Haines3, Melissa Mannion4, Matthew L. Stoll1, Timothy Beukelman1, Prescott Atkinson5 and Randy Q. Cron1, 1Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2Pediatrics, Assiut University, Assiut, Egypt, 3Pediatric Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL, 4Pediatrics, University of Alabama at Birmingham, Birmingham, AL, 5Pediatric Allergy and Immunology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Familial, or primary, hemophagocytic lymphohistiocytosis (pHLH), is a rare but highly fatal condition due to mutations in lymphocyte cytolytic pathway genes. Secondary HLH (sHLH),…
  • Abstract Number: 3 • 2017 Pediatric Rheumatology Symposium

    Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis: Results From an Open-Label, Long-Term Follow-up Study

    Hermine Brunner1, Nicolino Ruperto2, Pierre Quartier3, Tamás Constantin2, Ekaterina Alexeeva2, Rayfel Schneider4, Isabelle Koné-Paut5, Kenneth N. Schikler6, Katherine Marzan4, Nico Wulffraat2, Shai Padeh7, Vyacheslav Chasnyk7, Carine Wouters7, Jasmin B. Kuemmerle-Deschner7, Tilmann Kallinich7, Bernard Lauwerys8, Elie Haddad4, Evgeny L Nasonov7, Maria Trachana7, Olga Vougiouka7, Karolynn Leon9, Antonio Speziale10, Karine Lheritier10, Eleni Vritzali11, Alberto Martini7 and Daniel Lovell4, 1Rheumatology, PRCSG, Cincinnati, OH, 2PRINTO-Istituto Gaslini, Genoa, Italy, 3Necker-Enfants Malades Hospital, Paris, France, 4PRCSG, Cincinnati, OH, 5Hôpital Kremlin Bicetre, University of Paris SUD, Paris, France, 6PRCSG, Cincinatti, OH, 7PRINTO-Istituto Gaslini, Genova, Italy, 8Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels, Belgium, 9Novartis Pharmaceuticals Corporation, East Hanover, NJ, 10Novartis Pharma AG, Basel, Switzerland, 11Immunology and Dermatology Franchise, Novartis Pharma AG, Basel, Switzerland

    Background/Purpose:  Canakinumab (CAN), a selective human anti-IL1 β monoclonal antibody, had demonstrated its efficacy and safety in patients (pts) with active systemic juvenile idiopathic arthritis…
  • 1
  • 2
  • 3
  • …
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences